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Abstract 
Antiviral drugs have been known to prolong the lives of HIV infected 
patients. However, it is still uncertain if antiviral drugs affect the rate of 
virion clearance, the loss of target cells, or both. In this study, we used 
mathematical models to measure the effects of a protease inhibitor on three 
infected patients. After analysis of this data, we were able to calculate the 
lifespans of free virions and infected cells. We found that the antiviral drug 
decreased not only the number of free virions in the plasma but also the loss 
of infected target cells. Although this antiviral drug is not a cure for this 
disease, it can provide insight into creating an effective treatment program 
for HIV patients. 
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1 Introduction 
Researchers have been trying to understand why the human immunodefi-
ciency virus (HIV) leads to the collapse of the immune system. One hypoth-
esis is that HIV destroys target cells that have CD4 receptors. These target 
cells, or white blood cells, are crucial to the immune system. Once infected, 
a target cell becomes a virus-producing cell. Mter about seven hours, the 
target cell releases free virions into the plasma either by budding or erupting. 
In a recent study, plasma levels of HIV -1 were shown to decrease expo-
nentially after an antiviral drug was administered to five patients (Ho et al. 
1996). The antiviral drug, known as Ritonavir, is a protease inhibitor that 
prevents the virus from producing core proteins necessary for viral infection. 
These core proteins include RNA, gag, and pol proteins (Schupbach 1990). 
Ritonavir has only been on the market since 1996. Since Ritonavir's lifes-
pan is only 8-10 hours, HIV patients need to take the drug consistently; the 
recommended dosage is 600mg twice a day (Ad). 
Our project initially studied the dynamics of HIV-1 replication rate using 
what we will refer to as the P-Model (Ho et al. 1996). Our main purpose was 
to estimate the clearance rate and the lifespan of free virions and infected T 
cells on simulated data from three patients over a ten-day period. By analyz-
ing the derivation of the P-Model, we were able to determine its efficiency for 
explaining the behavior of HIV replication. We realized that the P-Model's 
efficiency depends upon many unrealistic assumptions, and decided to take 
our research further. We came up with a model that takes into account the 
drug's efficiency, the fact that T cells replicate, and that there is an immune 
response. 
What we call the L-Model is 
dTidt A - k VT I p - J.LT + qk VT I p (1) 
Before treatment dT* jdt (1- q)kVT I p- t5T* (2) 
dVIdt Nt5T*- cV- qNkVTIP (3) 
dTidt A- k~TIP- J.LT + qk~T/P (4) 
After treatment dT* ldt (1- q)k~T/P- (r + t5)T* (5) 
d~jdt ¢Nt5T*- c~- qNkV1T/P (6) 
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(7) 
where the total concentration of virions in the plasma is V(t) = Vj(t)+ VN1 (t). 
Vj(t) is the plasma concentration of virions in the infectious pool and VN1(t) 
is the concentration of virions in the noninfected pool. At the beginning of 
the treatment, when time is zero, Vi(O) = Vo and VN1 (0) = 0. 
Variables 
V(t) 
Vi(t) 
T 
T* 
Unknown 
the concentration of viral particles in plasma at time t. 
the plasma concentrations of virions in the infectious pool. 
produced before the drug's application, Vi(O) = Vo. 
the concentration of viral particles in the noninfectious pool. 
produced after the drug's application, Vni(O) = 0. 
target cells. 
virus-producing cells. 
N number of new virions produced per infected cell during its lifetime. 
N virions killed by each T, 
Parameters 
q proportion of successful attacks by the T cells. 
T / P probability of T cell infection. 
A constant recruitment rate. 
J-t per capita death rate. 
¢; drug efficiency. 
P total population of T cells. 
k the rate at which HIV infects target cells. 
c the viral clearance rate. 
8 the loss rate of infected cells. 
In this paper we find a solution in terms of Vo, c, and 8 for the total 
concentration of virions in the plasma at time t. We then use this solution 
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and the data to estimate c and b. Next, we compute the half life of free 
virions and interpret the average lifespan of a virion, an infected cell, and 
the average generation time of the virus. In the following section we estimate 
parameters and compare the predictions of a different model with results from 
the average lifespan of a virion, an infected cell, and the average generation 
time. We conclude with remarks on the biological implications of our results. 
2 Interpretation of the L-Model 
What we have named the 1-Model is an extension of our initial project. It 
takes into account the T cells' dynamics and the immune system's defense 
reaction; therefore, it includes such factors as the rate of change ofT cells, the 
recruitment rate, the mortality rate of T cells, and the number of successful 
attacks by T cells on the virions. These important elements, omitted in the P-
Model, are now taken into account to provide a more accurate analysis. Like 
the P-Model, the L-Model contains two parts: before and after treatment. 
As we analyze the change ofT cells with respect to time, before treatment 
we see that there is a recruitment rate as well as a result of the interaction 
between the virions and the T cells. There is also a mortality rate, reducing 
the number of T cells. Successful attacks by the immune system on the 
virus reduce the number of infected T cells. Changes in the number of 
infected T cells relative to time are also affected by the loss rate of infected 
T cells. As the number of infected T cells increases, so does the number of 
virions, but as the population of virions grows there is a portion of virions 
being eliminated by the clearance rate and by the immune system's successful 
attacks. Similarly, the "after-treatment" portion of the 1-Model includes an 
analysis of changes in the number of T cells with respect to time. This 
change is almost identical to the one before treatment, except that this time 
only the infectious virions affect the normal T cells. This is because the 
only virions that the T cells recognize are the initial ones. Likewise, the 
change in the number of infected T cells after treatment is similar to that 
of before treatment except that the mortality rate of T cells influences the 
number of infected T cells. There are two types of virions, the infectious and 
the noninfectious. The change in the number of infectious virions relative to 
time is related to the drug's effectiveness since the drug is not 100% effective. 
The term ¢N8T* represents infectious virions that the T cells continue to 
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attack after treatment. The number of noninfectious T cells is related to the 
drug's effectiveness and the clearance rate. 
In comparison to the P-Model, the L-Model is a better fit for reality be-
cause it relaxes most of the assumptions made in the P-Model. The L-Model 
makes only three assumptions: it assumes that the drug is administered once 
and that its effectiveness is a constant function of time; it also assumes low 
initial estimates for the number of new virions produced per infected T cell 
during its lifetime, and for the number of virions killed by one T cell. 
3 Solving for the Concentration of Virions 
By simplifying the L-Model and utilizing a few mathematical methods of 
approximation, we were able to find appropriate estimates for the viral clear-
ance rate, denoted by c, and the loss rate of infected T cells, denoted by 
8. In order to simplify the L-Model, we considered the situation when we 
have a 100% effective drug (i.e., ¢ = 0) and when the T cells are unable to 
attack the virus (i.e., q = 0). In addition, we must also make the following 
assumption for simplification purposes: T cells are initially at a quasi-steady 
state. This implies that the replication rate of T cells relative to time, in 
comparison to the replication rate of HIV-1 relative to time, is negligible 
(i.e., dT jdt = 0). Thus the number ofT cells is considered to be constant 
throughout the steady period. In dealing with such a small-time interval 
(To), we can also neglect the mortality rate of normally producing T cells 
(i.e., p,T = 0). 
Given these assumptions, we can eliminate equations (1) and (4) from 
the system, as well as any component containing ¢ or q to obtain: 
Before treatment dT*jdt kVT- 8T* (8) 
dVjdt N8T*- cV (9) 
dT*jdt k~T- 8T* (10) 
After treatment d~jdt -c~ (11) 
dVNJ/dt N8T*- cVNI, (12) 
As a result of this elimination process, we are able to derive the P-Model 
from the L-Model. With this system of five nonlinear differential equations 
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and a few assumptions, we can derive a solution for the number of virions in 
the plasma at timet. 
Several assumptions are included in this model to simplify the analysis 
of HIV's behavior under drug treatment. First of all, we assume that the 
HIV-1 virus infects a target cell at a constant rate k, at which time it takes 
on the role of a productively infected cell, T*. Second, we assume the drug is 
100% effective and that the number of target cells remains constant. Further-
more, we assume infected cells do not recover during the treatment period, 
to reduce the complications on the estimation of c and d. We also assume 
that the system describing the dynamics of HIV-1's reproduction rate is at a 
quasi-steady state, that is, that dT* jdt = 0 and dV/dt = 0 before the drug 
treatment. This assumption may be reasonable if the uninfected cell con-
centration stays at its steady state level for approximately a week after the 
administration of Ritonavir. Given these assumptions, the model becomes 
simple enough that an interpretation of the dynamics of the virus is possible 
(a caricature). 
Using the P-Model, we were able to derive a mathematical expression for 
the total concentration of virions at time t that depends only on the initial 
number of virions, Vo, the rate of virion clearance, c, and the loss rate of in-
fected cells 8. To analyze the replication rate of HIV-1 under drug treatment, 
we assume that (at the moment we start the treatment) the replication rate 
of infected T cells and of virions is zero. Thus dT jdt = 0 and dV/dt = 0. We 
also assume that the level, T0 , remains constant for the first week after the 
drug is administered. In other words, we assume that T remains at a steady 
state for one week after the drug is administered. 
Then we obtain the number of infectious virions V(t) by using separation 
of variables to integrate equation (11): 
JVI(t) dVI 
Vo ll[ 
lot -edt 
In llllll~~(t) 
-ct ~~ 
=?- ln IVI(t)l -ln !Vol -ct 
ln I V0at) I -ct (13) 
lnl v,(t) I 
e vo ect 
6 
IV~t)l 
Vj(t) TT -ct v0e . 
Next, in order to find the number of noninfectious virions in the plasma, we 
solve equations (10) and (12). First we solve forT* after we substitute our 
last result for Vj(t) into equation (10) 
dT* 
- = kVr0e-r:tT- 8T dt ' 
and since T is constant then 
dT* Vr -ct 8 * & = k oe To- T. 
Using the integrating factor technique yields 
dT* 
e6t & + 8e6tT* = k Voe6-r:tTo. 
This expression can be written 
Changing the variable of integration we get 
T*(t)e6t- T*(O) 
T*(t)e6t 
T*(t) 
T*(t) = 
lot kVoToe(6-c)sds 
k VoTo (et(6-c) _ 1) 
8-c 
kVoTo (et(6-c) _ 1) + T*(O) 
8-c 
[ ~~~ ( et(6-c) _ 1) + r;] e-6t 
[kVoTo (et(
6
-c) -1) + (8- c)T0] 
8-c 
where T0 is the initial value of T* ( t). 
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(14) 
Assuming that we are in a quasi steady-state so that dT* fdt = 0, it 
follows from equation (8) that if T0, Vo, and T0 are the initial conditions of 
T*, V, and T, respectively, then kdVoTo = 8T0·. Making this substitution, 
equation (14) becomes 
T*(t) = e-6t' [ [T08 (et(o-c)- 1) + (8- c)T0)] 
8-c (15) 
8-c 
T.* 
_o_ (8e-ct- ce-ot). 
8-c 
Next we substitute this expression for T*(t) into equation (12) and solve for 
VN1 (t), obtaining the number of noninfectious virions in the plasma: 
dVNI 
--+cVNI dt 
Using the integrating factor technique yields 
8-c 
N82To ct -6t 
x ce e 
v-c 
No2r.•t ( ) ( ) VNiect = ~ c~o e c-6't,since VNI(O) = 0. 
Now equation (9) and dV/dt = 0 implies N8T0 
substitution equation (16) can be rewritten as 
VN1(t) = --0 8te-ct- -- + --N8T.* ( ce-6t ce-ct) 8-c 8-c c-8 
8 
(16) 
cVo, and with this 
-- ute --- e e N8T; (~: -ct c ( -ot -ct)) 8-c 8-c 
N8T; ( c ( -ot -ct) ~: ct 
-- -- e - e - ute 
c-8 8-c · 
VNr(t) = cVo (-c-(e-6t- e-ct) - 8te-ct. 
c-8 c-8 
(17) 
Hence, using equations (13) and (17) the total number of virions in the 
plasma at time t 
V(t) = VI(t) + VNr(t) 
can be expressed as 
V(t) = VQe-ct + cVQ (-c-(e-ct- 8te-ct). 
c-8 c-8 
Given this solution, we can obtain appropriate values for the parameters for c 
and 8 using various mathematical techniques. This work is described below. 
4 Estimation of c and 8 
We estimated the clearance rate of virions and the loss rate of infected 
cells by using the Mathematica's packages NonlinearFit, Statistica Nonlinear 
Regression Analysis, Least Squares Method, and Find Minimum Program. 
The Mathematica NonlinearFit Package applies internally to Quasi New-
ton's Method, which gives the best approximations for the parameters of 
nonlinear multivariable equations. Here we entered the data of virions pro-
duced for all three patients. For each patient, we found estimates for Vo, c, 
and 8, using the solution of V(t) and giving initial estimates to these pa-
rameters. We then computed the average estimates for VQ, c, and 8. These 
approximations enabled us to graph the P-Model by plotting the average pre-
dicted values. Finally, we used Mathematica to compute the relative error of 
the P-Model with respect to the data observed, applying the relative error 
formula to the data of each patient. Thus, we obtained converging values 
for every parameter with a minimum error. Similarly, the Statistica Non-
linear Regression analysis package provided these minimum estimates, but 
for a more complicated case. The Regression Analysis Package, unlike the 
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NonlinearFit, applied the Quasi Newton's Method to the observed data for 
all patients simultaneously. As a result, it yielded the average estimates of 
the parameters. The FindMinimum program, unlike the two aforementioned 
methods, takes much longer and incorporates more steps to compute the best 
parameter approximations. 
5 Graphical Analysis of the Latino and Perel-
som Models 
The decline that occurs in the number of virions in the plasma after the 
drug is administered to the three patients can be interpreted graphically. By 
graphing the solution to the P-Model V(t) and using the obtained average 
parameter values of c, 8, and the initial number of virions, Vo, we observe an 
exponential decay in the number of virons as time progresses (see Figure 1). 
Initially we see a delay in the decline of virions, followed by a rapid, 
then a slower, decline. The delay that occurs in the first few hours is due 
to the amount of time needed for the drug's absorption, distribution, and 
penetration. The slow rate of decay in the number of virions during the 
last hours of the treatment period results from the dissipation of the drug's 
concentration. 
By comparing the predicted data with the observed data we can conclude 
that the P-Model, under the assumptions made, accurately describes the 
replication dynamics of HIV-1. This model provides a well-fitting curve for 
the observed data of each of the patients (Figures 2a-2c). The deviation from 
the curve to the observed data is almost insignificant, yet as we approach the 
end of the 10-day trial period this deviation increases. The efficiency of this 
model for all three cases under study is reflected in the relative error rate of 
each patient. As time goes by, the relative error for each patient increases 
(Table 1). 
We used Matlab to simulate our model. We created a program to find the 
best number of parameters fork, ¢;, and q, then we graphed the functions of 
V[, T, T*, and VNI to see the behavior of the graphs. Finally, we analyzed 
the graphs to see if these behaviors are consistent with biological behavior. 
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6 Comparison of the P-Model to the Wei et 
al. Model 
V(t; c, 8) = [Vo/( c- 8)] ( ce-6t- 8e-ct) (18) 
This model was introduced by Wei et al. (1995) and its symmetrical formula-
tion does not allow us to distinguish between the viral clearance rate and the 
loss rate of infected T cells. In addition to this ambiguity involved in finding 
parametric values for c and 8, we find that the nonlinear regression analysis 
utilized in finding estimates for c and d in the P-Model is not suitable for 
this model. Consequently, use of this data-fitting procedure in the Wei et 
al. (1995) model only establishes the fact that it is sensitive to the initial 
conditions chosen; that is, a slight alteration of the initial conditions for c 
and 8 yields entirely different results for their minimum values as processed 
by the NonlinearFit package. 
In order to demonstrate the limitations of equation (18) for distinguishing 
the parameters c and 8, we observe that V(t; c,8) = V(t; 8, c). Therefore, if 
we tried to compute values for c and 8 we would not be able to distinguish 
between them. 
7 Analysis of the Drug's Effectiveness(¢) Ac-
cording to the L-Model 
When the drug is 100% effective¢= 0, and when the drug is completely 
ineffective ¢ = 1. Therefore, as ¢ approaches 1 (i.e., as the drug loses its 
efficiency), the number of noninfectious virions approaches zero. This implies 
that at¢= 1 the drug's effectiveness has ceased, thereby causing the patients 
to revert to their condition before treatment. 
The drug's effectiveness eventually diminishes (i.e., ¢- 1). With time 
the virus builds resistance and the drug's concentration in the blood stream 
vanishes. In order for the patients not to return to their condition before 
treatment, we must administer the drug periodically. Since the drug's effec-
tiveness changes periodically with time, it must contain a periodic component 
accounting for the resistance it encounters, ¢. 
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After administering a protease inhibitor drug Ritonavir in two different 
strengths, the percentages of infectious virions (Vi), noninfectious virions 
(VNI), T cells (T), and infectious viron-producing T-cells (T*) change. This 
variation is directly affected by the strength of the drug. Histograms allow us 
to approximate the percentages of virions and cells, and also explain Graph 
1. 
Analyzing the number of virions before treatment (Histogram 1), we ob-
serve that all of the virions produced before the drug's administration are 
infectious (Vi). In analyzing the number of infected and noninfected T cells 
before the drug, we assume that 100% of the cells before treatment are pro-
ducing only infectious virions. After the drug is administered, we divide our 
observations into two categories: the first one is when we have a drug that is 
99% effective, and the second one is when the drug is 10% effective. When 
we use a 99% effective drug, we observe the percentage of healthy T-cells is 
greater. This is because the drug is stopping the production of infectious 
virions; therefore, there are not enough virions to infect T-cells. 
In Histogram 2a, we use an extremely efficient drug (99% effective). A 
drug this efficient will transform cells from infectious virion-producing (T*) 
to noninfectious viron-producing cells (T). The greater number ofT will 
show a large population of VNI· On the other hand, in Histogram 2b, when 
the drug is only 10% effective, the percentage of infected virions will be 
higher than the noninfected ones (mainly because of the drug's inefficency in 
protecting cells from becoming T*). By using a less effective drug, we have 
a tremendous production of infectious virions (Vi); these virions will infect a 
greater number ofT -cells, consequenly converting them into infectious T -cells 
(T*) at a fast rate. 
Results 
Figure 1 measures the predicted values for the number of free virions in 
the plasma over a 10-day period. If we use the P-Model, we expect to see an 
initial delay followed by a rapid then a slow decrease in the number of free 
virions. This initial delay is less than a day. The number of virions decreases 
to zero at the end of 10 days. 
In Figures 2a-2c, the observed and predicted values are plotted for the 
three patients. The number of free virions does decrease over time. These 
results are consistent with our predicted values (refer to Figure 1 for the 
predicted values). 
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Figure 3 measures the predicted number of infected virions when the 
drug's efficiency is 10%, 50%, and 99%. The dashed curve represents the 
drug's efficiency when it is 99%, the middle curve when it is 50%, and the 
top curve when it is 10%. Q represents the number of successful attacks by 
T cells when the T cell count is 1%. When the drug's efficiency is 99%, the 
number of infected virions approaches zero after two days. The number of 
infected virions is significantly higher when the drug's efficiency is 10 
Figure 4 measures the predicted number of noninfectious virions for drug 
efficiencies of 10%, 50%, and 99%. When the drug is 99% effective, the 
number of noninfectious virions reaches a peak of 15 virions 1.5 days after 
treatment. Then there is a slow decline in the number of noninfectious virions 
over the 10-day period. The peak only reaches eight noninfectious virions for 
a drug efficiency of 50%, and two noninfectious virions for a drug efficiency 
of 10%. 
Figure 5 measures the predicted number ofT cells using the same drug. 
When the drug's efficiency is 99%, the T cell count remains constant at a 
value of 1.3295 x 104 cells. 
Figure 6 measures the predicted number of infected T cells. When the 
drug is 99% efficient, the number of infected T cells approaches zero. This 
occurs six days after drug treatment. When the drug is 50% effective, there is 
a gradual decrease in the number of infected T cells. However, there are still 
10 infected T cells remaining after 10 days of drug treatment. The number 
of infected T cells increases when the drug is 10% effective. 
8 Conclusion 
We look upon the work done here as only the beginning of an on-going 
learning process. Thus our work is not entirely conclusive. With this in 
mind, we offer to those individuals interested in expanding on our work some 
suggestions for improving the accuracy of our model. First, it is important to 
consider the long-term effects and treatment process for the antiviral drug. 
A long-term model would focus on the dynamics of HIV and include HIV's 
density, mutation rate, and drug resistance. Since HIV becomes resistant 
to Ritonavir, it is important to continue applying the drug. Reapplication 
can be modeled as a periodic funtion of time for the drug's effectiveness. 
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Graphically, we would expect to get a cyclic function which repeats itself 
every time the drug is applied. Over time, the total number of virions and 
infected T cells declines, but as soon as HIV builds resistance, the number 
of virions will increase dramatically. Therefore, if we consider a long-term 
effect we will expect a cyclic funtion which initially decreases then increases 
rapidly. 
To bring this model closer to reality, it is also essential to increase the 
sample size. Another suggestion for further research would be to administer 
more than one drug during the period of study. Although the list of ideas for 
further study is not exhaustive, we leave the generation of more interesting 
additions to our list up to the curious scientist in all of us. 
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Number of free virions as a function of time for each of the three patients. 
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